Search by Drug Name or NDC
NDC 42961-0234-03 Xpect Pain Away Extra Strength 250; 250; 65 mg/1; mg/1; mg/1 Details
Xpect Pain Away Extra Strength 250; 250; 65 mg/1; mg/1; mg/1
Xpect Pain Away Extra Strength is a ORAL TABLET in the HUMAN OTC DRUG category. It is labeled and distributed by Cintas Corporation. The primary component is ACETAMINOPHEN; ASPIRIN; CAFFEINE.
Product Information
| NDC | 42961-0234 |
|---|---|
| Product ID | 42961-234_9a0014c7-91ad-49c2-af03-55b6aa869fb6 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Xpect Pain Away Extra Strength |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Acetaminophen Aspirin Caffeine |
| Product Type | HUMAN OTC DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 250; 250; 65 |
| Active Ingredient Units | mg/1; mg/1; mg/1 |
| Substance Name | ACETAMINOPHEN; ASPIRIN; CAFFEINE |
| Labeler Name | Cintas Corporation |
| Pharmaceutical Class | Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [E |
| DEA Schedule | n/a |
| Marketing Category | OTC MONOGRAPH NOT FINAL |
| Application Number | part343 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 42961-0234-03 (42961023403)
| NDC Package Code | 42961-234-03 |
|---|---|
| Billing NDC | 42961023403 |
| Package | 125 PACKAGE in 1 BOX (42961-234-03) / 2 TABLET in 1 PACKAGE (42961-234-01) |
| Marketing Start Date | 2023-07-26 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |